HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

503.398

-20.475-3.91%

Number of Gainers:8

Number of Losers:24

Number of Flat:1

PE:- -

High:523.582

Open:523.582

Low:498.297

Close:523.873

Volume:119.87M

Turnover:3.20B

Market Cap:322.68B

Float Cap:286.07B

Loading ...

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live

New Zealand's Rua Bioscience FY Customer Revenue Jumps on Australia, NZ Growth

Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer

Simply Wall St.

CStone Pharmaceuticals Posts HY Loss of Rmb252.3 Million

HBM Holdings Appoints Youchen Chen and Ian Yi Liu as Executive Directors

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

HBM Holdings Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management

HBM Holdings-B (02142) Posts First-Half Profit of $64.85M, Down 11.16% Year-on-Year

Press Release: Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors

HBM Holdings Names CFO Youchen Chen Executive Director Amid Board Changes

Hbm Holdings - Yiping Rong Resigns as Executive Director Effective August 27, 2026

THOMSON REUTERS

Harbour Biomed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

THOMSON REUTERS

Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

Alphamab Oncology Swings to FY26 H1 Loss of RMB 40.46 Million; Revenue Falls 15.09% to RMB 271.24 Million

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Hbm Holdings H1 Revenue USD 122.5 Million

THOMSON REUTERS

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy

Great-Sun Foods Posts 250% Surge in Total Profit as Pharmaceutical Arm Begins Consolidation

Cstone Pharma-B Reports Interim Results with Revenue Surging 314.75% to RMB 205 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1574/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":503.39795,"timestamp":1788163726135,"preClose":523.8731,"halted":0,"volume":119868273,"delay":0,"changeRate":-0.039084,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-20.475159,"latestTime":"08-31 16:00:00","open":523.582,"high":523.582,"low":498.29733,"amount":3203299214.5,"amplitude":0.048265,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":3.909696,"peRate":137.956161,"turnoverRate":0.003654,"increases":8,"decrements":24,"flats":1,"marketCap":322680201168,"floatMarketCap":286067329608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":523.582,"amplitude":0.048265,"preClose":523.8731,"low":498.29733,"pbRate":"3.909696","latestPrice":503.39795,"volume":119868273,"delay":0,"open":523.582,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":496.742,"twentyDayClose":467.18,"sixtyDayClose":475.465,"secType":"PLATE","market":"HK","turnoverRate":0.003654,"peRate":137.956161,"marketCap":322680201168,"floatMarketCap":286067329608,"timestamp":1788163726135,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662203452","title":"Akeso's Losses Narrow in H1 as Revenue Climbs 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203452","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203452?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:06","pubTimestamp":1787875618,"startTime":"0","endTime":"0","summary":"Akeso  reported an attributable loss of 424.2 million yuan for the first half, narrowing from a loss of 570.1 million a year earlier.Loss per share stood at 0.46 yuan, compared with 0.64 yuan in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.The biotech company's revenue increased 28% year over year to 1.81 billion yuan for the six months ended June 30 from 1.41 billion yuan.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348766576.USD","LU1961090484.USD","BK1161","LU0417516738.SGD","LU2399975544.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU0348784397.USD","KURE","LU1720050803.USD","LU2778985437.USD","FCA","LU0348827113.USD","09926","LU2476274308.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0540923850.HKD","LU0348767384.USD","LU0634319403.HKD","BK1574","LU0348825331.USD","LU0348783233.USD","LU2488822045.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662103552","title":"New Zealand's Rua Bioscience FY Customer Revenue Jumps on Australia, NZ Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662103552","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662103552?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:08","pubTimestamp":1787864935,"startTime":"0","endTime":"0","summary":"New Zealand's Rua Bioscience FY customer revenue jumps on Australia, NZ growthOverviewNew Zealand medicinal cannabis firm's preliminary FY26 customer revenue rose 71% yr/yr to NZ$2.58 mlnPreliminary F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O18E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033496","title":"Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033496","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033496?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:29","pubTimestamp":1787858983,"startTime":"0","endTime":"0","summary":"Alphamab Oncology recently reported half-year 2026 results showing CNY 271.24 million in sales and a net loss of CNY 40.46 million, while also securing Chinese priority review for multiple Anbenitamab new drug applications in HER2-positive breast cancer.\nThe acceptance of these Anbenitamab applications, backed by a head-to-head phase III trial in advanced HER2-positive breast cancer, marks a rare case where a bispecific antibody combination outperformed the long-standing THP standard regimen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/why-alphamab-oncology-sehk9966-is-up-92-after-priority-revie","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/why-alphamab-oncology-sehk9966-is-up-92-after-priority-revie","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662934081","title":"CStone Pharmaceuticals Posts HY Loss of Rmb252.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662934081","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662934081?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:55","pubTimestamp":1787846119,"startTime":"0","endTime":"0","summary":"BRIEF-CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 MillionAug 27 (Reuters)-CStone Pharmaceuticals2616.HK:HY LOSS RMB252.3 MILLIONHY REVENUE RMB205.1 MILLIONNO DIVIDENDS PAID, DECLARED OR PROPOSED DURING INTERIM PERIODFurther company coverage:2616.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662089078","title":"HBM Holdings Appoints Youchen Chen and Ian Yi Liu as Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662089078","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662089078?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:34","pubTimestamp":1787844843,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Appoints Youchen Chen And Ian Yi Liu As Executive DirectorsAug 27 (Reuters)-Hbm Holdings Ltd2142.HK:APPOINTS YOUCHEN CHEN AND IAN YI LIU AS EXECUTIVE DIRECTORS EFFECTIVE AUGUST 27, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662955085","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2662955085","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662955085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:15","pubTimestamp":1787840100,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherapy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDXJ","LU1093756168.USD","BK4533","CDE","LU1721428933.USD","BK4567","LU0053666078.USD","BK4121","BK4107","02616","PFS","LU0210528500.USD","MTD","LU0347712357.USD","BK4585","LU1223082519.USD","IND","BK4017","SIL","XME","L","LU1093756325.SGD","LU2487616109.SGD","SGDM","LU2413666426.HKD","LU2211817866.USD","IE00B5TLWC47.USD","IE00BFXG0V08.USD","ORR","BK1574","BK4548","BK4588","BK1161","LU2413666699.HKD","BK4211","IE00BYQQ9H92.USD","BK4195","LU1223083913.SGD","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085572","title":"HBM Holdings Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085572","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085572?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:14","pubTimestamp":1787840073,"startTime":"0","endTime":"0","summary":"HBM Holdings files list of directors, board committee memberships and disclosure-responsible managementHBM Holdings set its board lineup as of Aug. 27, 2026, naming Dr. Jingsong Wang as chairman, chie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL4g9Z1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196427827","title":"HBM Holdings-B (02142) Posts First-Half Profit of $64.85M, Down 11.16% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1196427827","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196427827?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:14","pubTimestamp":1787840065,"startTime":"0","endTime":"0","summary":"HBM Holdings-B (02142) has announced its interim results for the six months ended June 30, 2026, reporting total revenue of $122 million, a 20.9% increase year-on-year. The company recorded a profit...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085546","title":"Press Release: Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085546","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085546?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:09","pubTimestamp":1787839740,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and deve","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","TM","BK4099","BK1574","BK4585","BK4588","BK1583","BK4022","BK4604","03160","BK4232","BK4555","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085817","title":"HBM Holdings Names CFO Youchen Chen Executive Director Amid Board Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085817","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085817?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:07","pubTimestamp":1787839667,"startTime":"0","endTime":"0","summary":"HBM Holdings names CFO Youchen Chen executive director amid board changesHBM Holdings named CFO Youchen Chen and legal chief Ian Yi Liu as executive directors, effective Aug. 27, 2026.Executive direct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL58VqTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1189","BK1518","BK1574","02158","BK1583","BK1161","00656","BK1617","BK1230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662899085","title":"Hbm Holdings - Yiping Rong Resigns as Executive Director Effective August 27, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662899085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662899085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:07","pubTimestamp":1787839630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1HP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662021083","title":"Harbour Biomed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662021083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662021083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA91JKGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085166","title":"Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085166","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085166?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839500,"startTime":"0","endTime":"0","summary":"established out-licensing agreements for innovative products, and strong. -- Profit for the period reached US$64.9 million, and adjusted net profit. for the period[1] was approximately US$71.6 million, marking seven","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","R","BK4022","CNS","BK1583","BK1574","MSS","AAQC","BK4232","BK4113","BK4135","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662608309","title":"Alphamab Oncology Swings to FY26 H1 Loss of RMB 40.46 Million; Revenue Falls 15.09% to RMB 271.24 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662608309","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662608309?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:03","pubTimestamp":1787839411,"startTime":"0","endTime":"0","summary":"Alphamab Oncology swings to FY26 H1 loss of RMB 40.46 million; revenue falls 15.09% to RMB 271.24 millionAlphamab Oncology posted a loss of RMB 40.46 million, swinging from a profit of RMB 21.58 milli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL6fG19l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BIB","BK4533","LU0109394709.USD","BK1161","BK1574","LU1983299246.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU2089984988.USD","LU2242646821.SGD","LU0058720904.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4139","IE00BFTCPJ56.SGD","AMGN","BK4566","IE0002141913.USD","LU1571399168.USD","LU2468319806.SGD","BK4599","TBXU","PJP","LU1061106388.HKD","LU0889565916.HKD","LU2242652126.USD","BK4581","PBE","LU0289739699.SGD","IBBQ","IBB","LU0320765992.SGD","02142","IE00B2B36J28.USD","BK1583","LU1057294990.SGD","LU2112291526.USD","LU0868494617.USD","BK4585","BK4534","BBH","SG9999001440.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662083779","title":"Hbm Holdings H1 Revenue USD 122.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662083779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662083779?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX0KDRVX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790083","title":"Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:00","pubTimestamp":1787839249,"startTime":"0","endTime":"0","summary":"Akeso FY26 H1 net loss narrows 23.98% to RMB 447.2 million; revenue rises 27.92% to RMB 1.81 billionAkeso posted revenue of RMB 1.81 billion, up 27.92% year over year, driven mainly by cadonilimab and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL34jFkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU1961090484.USD","LU2476274720.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","LU0348735423.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348766576.USD","LU0417516738.SGD","KURE","LU0348825331.USD","LU2399975544.HKD","BK1574","LU2488822045.USD","BK1161","LU0540923850.HKD","LU0348767384.USD","LU2778985437.USD","LU0348827113.USD","LU0634319403.HKD","LU0417516902.SGD","09926","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191561333","title":"TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1191561333","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191561333?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:26","pubTimestamp":1787837163,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that its independently developed next-generation EGFR-TKI innovative drug, Duxenaitinib Mesylate Tablets (TY-9591), has received conditional marketing approval...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1574","09939","BK1161","IPOS","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167119384","title":"Great-Sun Foods Posts 250% Surge in Total Profit as Pharmaceutical Arm Begins Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=1167119384","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167119384?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:22","pubTimestamp":1787833347,"startTime":"0","endTime":"0","summary":"Great-Sun Foods Co.,Ltd. (603336.SH) released its 2026 semi-annual report on the evening of August 27. Despite short-term pressure in its core fruit and vegetable business due to industry cycles, the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","BK0238","BK1161","603336","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146657120","title":"Cstone Pharma-B Reports Interim Results with Revenue Surging 314.75% to RMB 205 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1146657120","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146657120?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:42","pubTimestamp":1787830948,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) has released its interim results for the six months ended June 30, 2026, showing a substantial revenue increase of 314.75% to RMB 205 million. The company reported a loss of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":5,"totalSize":375,"code":"91000000","status":"200"}]}}